-DOCSTART- -X- O
Molecular -X- _ O
imaging -X- _ O
with -X- _ O
single -X- _ O
photon- -X- _ O
and -X- _ O
positron-emitting -X- _ O
tracers -X- _ O
plays -X- _ O
an -X- _ O
important -X- _ O
role -X- _ O
in -X- _ O
the -X- _ O
evaluation -X- _ O
of -X- _ O
inflammation -X- _ O
and -X- _ O
infection. -X- _ O
Although -X- _ O
supplanted -X- _ O
by -X- _ O
labeled -X- _ O
leukocyte -X- _ O
imaging -X- _ O
for -X- _ O
most -X- _ O
indications -X- _ O
, -X- _ O
gallium-67 -X- _ B-Intervention
remains -X- _ O
useful -X- _ B-Outcome
for -X- _ I-Outcome
opportunistic -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
pulmonary -X- _ I-Outcome
inflammation -X- _ I-Outcome
and -X- _ I-Outcome
interstitial -X- _ I-Outcome
nephritis -X- _ I-Outcome
and -X- _ I-Outcome
, -X- _ I-Outcome
when -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
18 -X- _ I-Outcome
) -X- _ I-Outcome
F -X- _ I-Outcome
] -X- _ I-Outcome
FDG -X- _ I-Outcome
is -X- _ I-Outcome
not -X- _ I-Outcome
available -X- _ I-Outcome
, -X- _ I-Outcome
spinal -X- _ I-Outcome
infection -X- _ I-Outcome
and -X- _ I-Outcome
fever -X- _ I-Outcome
of -X- _ I-Outcome
unknown -X- _ I-Outcome
origin. -X- _ I-Outcome
In -X- _ B-Intervention
vitro -X- _ I-Intervention
labeled -X- _ I-Intervention
leukocyte -X- _ I-Intervention
imaging -X- _ I-Intervention
is -X- _ O
the -X- _ O
radionuclide -X- _ O
procedure -X- _ O
of -X- _ O
choice -X- _ O
for -X- _ B-Outcome
most -X- _ I-Outcome
infections -X- _ I-Outcome
in -X- _ I-Outcome
immunocompetent -X- _ I-Outcome
patients. -X- _ I-Outcome
When -X- _ O
performed -X- _ O
for -X- _ O
musculoskeletal -X- _ O
infection -X- _ O
, -X- _ O
complementary -X- _ O
bone -X- _ O
marrow -X- _ O
imaging -X- _ O
usually -X- _ O
is -X- _ O
necessary. -X- _ O
Recent -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
dual -X- _ O
time -X- _ O
point -X- _ O
imaging -X- _ O
might -X- _ O
be -X- _ O
an -X- _ O
alternative -X- _ O
to -X- _ O
marrow -X- _ O
imaging. -X- _ O
Several -X- _ O
methods -X- _ O
of -X- _ O
labeling -X- _ O
leukocytes -X- _ O
in -X- _ O
vivo -X- _ O
, -X- _ O
with -X- _ O
agents -X- _ O
including -X- _ O
antigranulocyte -X- _ O
antibodies -X- _ O
and -X- _ O
antibody -X- _ O
fragments -X- _ O
, -X- _ O
peptides -X- _ O
and -X- _ O
cytokines -X- _ O
, -X- _ O
have -X- _ O
been -X- _ O
investigated -X- _ O
, -X- _ O
with -X- _ O
variable -X- _ O
results. -X- _ O
These -X- _ O
agents -X- _ O
are -X- _ O
not -X- _ O
widely -X- _ O
available -X- _ O
and -X- _ O
none -X- _ O
of -X- _ O
them -X- _ O
are -X- _ O
available -X- _ O
in -X- _ O
the -X- _ O
USA. -X- _ O
Radiolabeled -X- _ O
antibiotics -X- _ O
have -X- _ O
been -X- _ O
investigated -X- _ O
as -X- _ O
“infection-specific” -X- _ O
tracers -X- _ O
, -X- _ O
but -X- _ O
the -X- _ O
results -X- _ O
to -X- _ O
date -X- _ O
have -X- _ O
been -X- _ O
disappointing. -X- _ O
Conversely -X- _ O
, -X- _ O
radiolabeled -X- _ B-Intervention
antimicrobial -X- _ I-Intervention
peptides -X- _ I-Intervention
do -X- _ O
hold -X- _ O
promise -X- _ O
as -X- _ O
infection-specific -X- _ O
tracers. -X- _ O
The -X- _ O
use -X- _ O
of -X- _ O
positron-emitting -X- _ O
tracers -X- _ O
for -X- _ O
diagnosing -X- _ O
inflammation -X- _ O
and -X- _ O
infection -X- _ O
has -X- _ O
generated -X- _ O
considerable -X- _ O
interest. -X- _ O
[ -X- _ B-Intervention
( -X- _ I-Intervention
18 -X- _ I-Intervention
) -X- _ I-Intervention
F -X- _ I-Intervention
] -X- _ I-Intervention
FDG -X- _ I-Intervention
is -X- _ O
useful -X- _ B-Outcome
in -X- _ I-Outcome
fever -X- _ I-Outcome
of -X- _ I-Outcome
unknown -X- _ I-Outcome
origin -X- _ I-Outcome
, -X- _ I-Outcome
spinal -X- _ I-Outcome
osteomyelitis -X- _ I-Outcome
, -X- _ I-Outcome
vasculitis -X- _ I-Outcome
and -X- _ I-Outcome
sarcoidosis. -X- _ I-Outcome
Other -X- _ O
positron-emitting -X- _ O
tracers -X- _ O
that -X- _ O
have -X- _ O
been -X- _ O
investigated -X- _ O
include -X- _ O
[ -X- _ B-Intervention
( -X- _ I-Intervention
18 -X- _ I-Intervention
) -X- _ I-Intervention
F -X- _ I-Intervention
] -X- _ I-Intervention
FDGlabeled -X- _ I-Intervention
leukocytes -X- _ I-Intervention
, -X- _ I-Intervention
copper-64-labeled -X- _ I-Intervention
leukocytes -X- _ I-Intervention
, -X- _ I-Intervention
gallium-68 -X- _ I-Intervention
citrate -X- _ I-Intervention
and -X- _ I-Intervention
iodine-124 -X- _ I-Intervention
FIAU. -X- _ I-Intervention
Although -X- _ O
radiolabeled -X- _ O
tracers -X- _ O
are -X- _ O
used -X- _ O
primarily -X- _ O
for -X- _ O
diagnosis -X- _ O
, -X- _ O
they -X- _ O
also -X- _ O
offer -X- _ O
objective -X- _ O
biomarkers -X- _ O
for -X- _ O
assessing -X- _ O
response -X- _ O
to -X- _ O
therapeutic -X- _ O
interventions -X- _ O
in -X- _ O
inflammatory -X- _ O
diseases. -X- _ O
They -X- _ O
could -X- _ O
also -X- _ O
potentially -X- _ O
be -X- _ O
used -X- _ O
to -X- _ O
target -X- _ O
cells -X- _ O
and -X- _ O
molecules -X- _ O
with -X- _ O
specific -X- _ O
receptor -X- _ O
expression -X- _ O
for -X- _ O
histological -X- _ O
characterization -X- _ O
, -X- _ O
select -X- _ O
patients -X- _ O
for -X- _ O
receptor-targeted -X- _ O
therapy -X- _ O
and -X- _ O
predict -X- _ O
response -X- _ O
to -X- _ O
treatment -X- _ O
. -X- _ O

